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Abstract
Background:  Small intestinal bacterial overgrowth (SIBO) is characterized by excessive
proliferation of colonic bacterial species in the small bowel. Potential causes of SIBO include
fistulae, strictures or motility disturbances. Hence, patients with Crohn's Disease (CD) are
especially predisposed to develop SIBO. As result, CD patients may experience malabsorption and
report symptoms such as weight loss, watery diarrhea, meteorism, flatulence and abdominal pain,
mimicking acute flare in these patients.
Methods: One-hundred-fifty patients with CD reporting increased stool frequency, meteorism
and/or abdominal pain were prospectively evaluated for SIBO with the Hydrogen Glucose Breath
Test (HGBT).
Results: Thirty-eight patients (25.3%) were diagnosed with SIBO based on positive findings at
HGBT. SIBO patients reported a higher rate of abdominal complaints and exhibited increased stool
frequency (5.9 vs. 3.7 bowel movements/day, p = 0.003) and lower body weight (63.6 vs 70.4 kg, p
= 0.014). There was no correlation with the Crohn's Disease Activity Index. SIBO was significantly
more frequent in patients with partial resection of the colon or multiple intestinal surgeries; there
was also a clear trend in patients with ileocecal resection that did not reach statistical significance.
SIBO rate was also higher in patients with affection of both the colon and small bowel, while
inflammation of the (neo)terminal ileum again showed only tendential association with the
development of SIBO.
Conclusion: SIBO represents a frequently ignored yet clinically relevant complication in CD, often
mimicking acute flare. Because symptoms of SIBO are often difficult to differentiate from those
caused by the underlying disease, targeted work-up is recommended in patients with
corresponding clinical signs and predisposing factors.
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Introduction
The small bowel represents a transition zone between the
stomach, which harbors low numbers of microorganisms,
and the colon, with its high level of bacterial colonization.
Small intestinal bacterial overgrowth (SIBO) represents
an increased colonization by bacterial species derived
from the colonic flora that may spread beyond the small
bowel segments and sometimes affect the stomach. Under
physiological conditions, the proximal jejunum is charac-
terized by a bacterial population corresponding to 103-
104 colony forming units (CFU) per milliliter of aspirate.
SIBO is characterized by a population corresponding to
>105 CFU/ml of aspirate [1-3].
Direct confirmation of SIBO is possible only by microbio-
logical examination of aspirate from the proximal small
bowel [1,4]. Because of the difficulty of integrating this
method into clinical routine, it has become standard pro-
cedure to utilize indirect non-invasive methods for detect-
ing SIBO based on changes caused by the metabolic
activity of bacteria colonizing these bowel segments.
Hydrogen Breath Tests (HBT) determine the concentra-
tion of hydrogen gas (H2) in exhaled air following the oral
administration of carbohydrates. H2 is produced exclu-
sively by bacteria; in healthy individuals, significant num-
bers of such bacteria are found only in the colon. H2 gas
formed in the bowel passes by diffusion into the capillary
circulation of the intestinal mucosa. Because of its low sol-
ubility in blood, it is completely eliminated through the
lungs in exhaled air. This production of H2 by intestinal
bacteria following oral application of carbohydrates can
be used diagnostically to demonstrate, among other enti-
ties, bacterial overgrowth of the upper gastrointestinal
tract with H2-forming microorganisms. A simple and sen-
sitive test for detecting bacterial overgrowth is the H2 glu-
cose breath test (HGBT). Physiologically absorbed
carbohydrates such as glucose undergo fermentation
mediated by bacteria prior to their absorption in the small
bowel. A by-product of this process is H2. An increase in
the H2 concentration in exhaled air (>10 ppm) over base-
line (H2 level prior to substrate intake) after oral applica-
tion of 50 mg of glucose is considered evidence of SIBO
[1,3-5].
As a consequence of maldigestion and inflammatory
changes of the bowel mucosal membrane secondary to
SIBO, patients experience a reduction in intestinal absorp-
tion. Malabsorption affects the intake of important nutri-
ents, like fat-soluble vitamins, and certain minerals, such
as calcium. SIBO also results in a constellation of symp-
toms including watery diarrhea, weight loss, meteorism,
flatulence and abdominal pain [1,5,6].
Factors promoting the development of SIBO include
changes in the acid secretion of the stomach, fistulae, stric-
tures and motility disturbances. In addition, an intact ile-
ocecal valve serves as a physiological barrier between the
small bowel and colon [1,7-9].
For these reasons, patients with Crohn's Disease (CD)
may exhibit a predisposition for SIBO.
There is a paucity of data in the literature regarding the
prevalence of SIBO in patients with CD [8-10]. In many
cases, bacterial overgrowth may be overlooked due to the
fact that the symptoms of SIBO do not differ significantly
from those of the underlying disease process itself some-
times even mimicking an acute flare.
This, in turn, may have as a consequence that therapeutic
measures, such as the administration of topical or sys-
temic steroids, may be instituted based on the potentially
incorrect assumption that patients' symptoms are the
result of increased disease activity. On the other hand,
SIBO can be treated with a short course of antibiotic ther-
apy [2,11-13].
Objective of the present prospective study was to investi-
gate the prevalence of small intestinal bacterial over-
growth (SIBO) and possible predisposing factors in a
selected group of patients with CD and increased stool fre-
quency and/or meteorism. Patients underwent H2 glucose
breath test (HGBT) to screen for SIBO and provided infor-
mation on their medical history using a standardized
questionnaire.
Methods
Patients
Two-hundred sixty-seven consecutive CD patients attend-
ing the Crohn's/Ulcerative Colitis Outpatient Clinic of the
University Hospital of Ulm received a written invitation to
participate in this study. Inclusion criteria included endo-
scopically or histologically confirmed CD and clinical
symptoms characterized by at least one of the following
symptoms: diarrhea (more than four bowel movements
per day), meteorism (lasting for more than two weeks)
and/or abdominal pain (occurring at least one to two
times per week, severity described as at least "moderate").
Exclusion criteria included use of antibiotics, therapy with
probiotics, history of bowel preparation for colonoscopy
within four weeks preceding study inclusion, treatment of
a stoma and abdominal complains such as nausea and
vomiting or abdominal colic suspected to be related to
bowel stricture or obstruction. Of the total 267 invited
patients, 150 patients (56.2%) fulfilled the inclusion cri-
teria. Eighty patients did not meet the inclusion criteria,
while the remaining 37 patients refused to participate in
the study without citing reasons. Disease activity wasBMC Gastroenterology 2009, 9:61 http://www.biomedcentral.com/1471-230X/9/61
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assessed on the basis of the Crohn's Disease Activity Index
(CDAI; [14]). Patients provided data on the clinical course
of their disease using a standardized questionnaire; miss-
ing data were supplied from the patients' medical records.
The study was conducted with the approval of the ethics
committee of the University of Ulm in accordance with
the principles of the Helsinki Declaration and the rules of
Good Clinical Practice. Written informed consent was
obtained from each patient prior to inclusion into the
study.
H2 Glucose Breath Test (HGBT)
The H2 Glucose Breath Test (HGBT) was performed on an
outpatient basis between 8:00 and 11:00 a.m. Patients
were asked to abstain from all food for at least 12 hours
prior to the test and to avoid high-carbohydrate meals on
the previous day. In addition, patients were asked not to
smoke for at least two hours prior to the test and to avoid
physical exertion. The first breath sample was taken as
baseline level. Thereafter, patients were given 50 grams of
glucose in 200 ml of uncarbonated mineral water. The
concentration of hydrogen in exhaled air was then meas-
ured every twenty minutes using a H2 analyzer (GMI Med-
ical Ltd., Renfrew, Scotland, UK). The duration of the test
was 180 minutes. An increase of more than 10 parts per
million (ppm) over baseline in at least three samples
within the measurement period was taken as evidence of
bacterial overgrowth in the small bowel [12].
Statistics
Results were evaluated descriptively. Continuous data
were represented as median with range. Because of the
non-normal distribution of continuous data within the
subgroups with and without evidence of SIBO, the Mann-
Whitney test was used as a non-parametric method. Dif-
ferences between groups were considered statistically sig-
nificant at values of p < 0.05. A comparison of frequencies
within the subgroups was performed using a four-field
test. Again, statistical significance was assigned for values
of p < 0.05.
Results
Patient demographics for all 150 study participants are
given in table 1. There was no statistically significant dif-
ference between males and females in terms of age and
average duration of the disease. As expected, males, on
average, exhibited significantly greater heights and
weights; however, they were comparable in terms of body-
mass index (BMI; table 1).
The diagnosis of small intestinal bacterial overgrowth
(SIBO) was made on the bases of the H2 Glucose Breath
Test (HGBT) in 38 patients (25.3%). HGBT results were
negative in the remaining 112 patients.
Due to the degree of clinical symptoms during the HGBT,
three patients with negative HGBT findings underwent the
H2 Lactulose Breath Test (HLBT). Based on the results of
HLBT, these three patients were classified as non-hydro-
gen producers. For the purposes of the present study, these
patients continued to be assigned to the group without
evidence of SIBO.
The groups of patients with and without SIBO did not dif-
fer in terms of age or height. The average weight of
patients with SIBO, however, was significantly lower
(63.6 kg vs. 70.4 kg, p = 0.014). Calculation of BMI also
showed lower values for the patient group with SIBO, but
the difference was not statistically significant (table 2).
There was no statistically significant difference between
patients with and without SIBO with respect to mean time
since first diagnosis (table 2), although the prevalence of
SIBO increased in proportion to the duration of the dis-
ease in comparison with the overall group. SIBO was
observed in 18 of 97 patients (18.6%) in whom less than
15 years had elapsed since the first diagnosis of Crohn's
disease, compared to 20 of 53 patients (37.7%) with a
greater than 15-year history of the disease. This difference,
however, remained just below the level set for statistical
significance in terms of the 95% confidence interval
(12.1–27.4% vs. 25.9–51.2%).
The daily stool frequency in patients with SIBO was signif-
icantly higher than in those without SIBO (5.9 vs. 3.7; p =
0.003; table 3). Stool frequency in excess of six bowel
movements per day was observed in 11 patients (28.9%)
with SIBO compared to only 13 patients (11.6%) in those
without SIBO (p = 0.012). Low stool frequencies of less
Table 1: Demographic data of the 150 patients included in the study
All (n = 150) Females (n = 91) Males (n = 59)
Age 41 (18–72) 40 (18–72) 43 (21–71)
Body weight (kg) 68.7 (43–125) 64.5 (43–125) 75.2 (48–104)
Height (cm) 169.9 (142–192) 165.0 (142–180) 177.4 (160–192)
BMI (kg/m2) 23.7 (17–39) 23.6 (17–39) 23.9 (17–32)
Disease duration (years) 11.7 (0.5–36) 10.7 (0.5–33) 13.3 (0.5–36)BMC Gastroenterology 2009, 9:61 http://www.biomedcentral.com/1471-230X/9/61
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than three bowel movements per day were observed in
only seven patients (18.4%) of patients with positive test
results compared to 49 patients (43.8%) with negative test
results (p = 0.005; table 3). By comparison, SIBO was
present significantly more often in patients with a daily
stool frequency of six or more bowel movements (45.8%;
95%-CI: 27.9–64.9%) than in those with less than three
bowel movements per day (12.5%; 95%-CI: 6.2–23.6%;
table 4).
Median CDAI in patients with SIBO was 166 (range: 34–
406) and was only tendentially higher than in patients
without SIBO (median: 139; range: 13–399; p = 0.098).
Of patients with SIBO, 17 (44.7%) had a CDAI <150 and
21 (55.3%), a CDAI >150. By comparison, 65 of 112
patients (58.0%) without SIBO had a CDAI <150 and 47
patients (42%) a CDAI >150.
All participants were asked whether they experienced
increased symptoms during the HGBT. Interestingly,
patients with SIBO reported increased symptoms during
the test significantly more often than did those without
SIBO (19 [50.0%] vs. 21 [18.8%]; p = 0.0002; table 5).
Reported symptoms included predominantly meteorism,
diarrhea and abdominal pain. Bloating was reported sig-
nificantly more often during the test in patients with SIBO
(44.7% vs. 10.7%). Symptoms occurring during adminis-
tration of the HGBT are given in table 5.
The pattern of inflammation in patients in relation to
SIBO is given in table 6. With respect to the pattern of
inflammation with disease involving the ileum there was
no significant difference between patients with and with-
out SIBO. Patients with SIBO, however, showed a trend
towards higher frequency of inflammation involving the
colon and a significantly higher frequency of combined
involvement of the colon and small bowel than did
patients without SIBO.
Fourteen of 37 patients (37.8%) with inflammation
involving the colon and small bowel at the time of the
study exhibited SIBO. SIBO was present in 24 of 77
patients (26.8%) with inflammation exclusively affecting
the colon and in 27 of 99 patients (18.8%) with inflam-
mation exclusively affecting the ileum.
Frequency and site of prior surgical procedures in relation
to SIBO are given in table 6. Twenty-three of 71 patients
(32.4%) who had undergone ileocecal resection tested
positive for SIBO. Of the 79 patients with intact ileocecal
valve, however, only 15 patients (19.0%) tested positive
for SIBO (p = 0.059). Patients with prior colectomy
returned pathological breath test findings in 10 of 23
cases (43.5%). By comparison, only 28 of 127 patients
who had not undergone prior colectomy returned positive
findings (p = 0.030). Thus, patients with prior colectomy
or with multiple prior surgical procedures involving the
bowel showed a significantly higher rate of SIBO; patients
with prior ileocecal resection also exhibited a higher rate
of SIBO, but the difference did not achieve statistical sig-
nificance.
Patients with or without SIBO showed no differences in
terms of their pharmacological Crohn's therapy and there
was no correlation between the occurrence of SIBO and
patient's current treatment with 5-aminosalicylic acid,
topical or systemic steroids or immunosuppressants.
Table 2: Age, body weight and height, and duration of disease in relation to results of the H2-Glucose breath test.
SIBO (n = 38) No SIBO (n = 112) p
Age 41 (21–62) 41 (18–72) 0.887
Body weight (kg) 63.6 (43–100) 70.4 (43–125) 0.014
Body height (cm) 167.9 (147–188) 170.5 (142–192) 0.174
BMI (kg/m2) 22.5 (17–32) 24.1 (17–39) 0.064
Disease duration (years) 13.6 (0.75–31) 11.1 (0.5–36) 0.113
Table 3: Average daily stool frequency, low, medium and high stool frequencies in patients with an without SIBO
SIBO (n = 38) No SIBO (n = 112)
n%n% p
< 3 stools/day 7 18.4% 49 43.8% 0.005
3–6 stools/day 20 52.6% 50 44.6% 0.394
> 6 stools/day 11 28.9% 13 11.6% 0.012
Median 95%-CI Range Median 95%-CI Range
stools per day 5.9 +/- 1.9 1–22 3.7 +/- 0.5 1–15 0.003BMC Gastroenterology 2009, 9:61 http://www.biomedcentral.com/1471-230X/9/61
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Reduced gastric acid secretion may promote bacterial
growth. Of 13 patients receiving proton pump inhibitors
at the time of HGBT, five returned positive findings
(38.5%). Of the 137 patients who did not use acid-reduc-
ing agents, only 33 showed evidence of SIBO (24.1%; p =
0.255).
Smokers may exhibit increased H2 production and lead to
false positive test results. Both the proportion of smokers
(34.2% vs. 27.7%; p = 0.445) and their respective daily
consumption of cigarettes (10.5 vs. 11.4 cigarettes per
day; p = 0.473) were comparable in both groups.
Discussion
Bacterial overgrowth of the small bowel (SIBO) has been
described in association with a variety of disorders,
including Crohn's disease (CD). To date, however, there is
a paucity of data in the international literature addressing
this complication, even though CD patients often exhibit
a predisposition for SIBO. The current prospective study
investigated the prevalence, predisposing factors and clin-
ical relevance of SIBO in patients with CD. We found that
fully a quarter of all patients (38/150, 25.3%) with CD
and abdominal complaints suffer from SIBO.
This figure is in agreement with findings published by
Castiglione et al. [8] and Rutgeerts et al. [9], who found
SIBO in 23–25% of patients with CD, although their stud-
ies were conducted with much smaller numbers of
patients. Castiglione et al. used the H2-lactulose breath
test (HLBT) to screen for the presence of bacterial over-
growth in a group of 57 patients with either intact or sur-
gically resected ileocecal valves [8]. The collective studied
by Rutgeerts et al. included 61 patients who had not
undergone prior surgery [9].
The H2-glucose breath test (HGBT) used in this study is
reported in the literature to have a sensitivity of 62–93%
and a specificity of 78–100% in detecting SIBO [1,3]. The
H2-lactulose breath test (HLBT), however, which detects
bacterial overgrowth by determining the oro-cecal transit
time, shows a sensitivity of only 16.7–68% and a specifi-
city of 44–70% [1,3]. Although some studies have sug-
gested a possible superiority of the 14C-xylose breath test
(XBT), which uses 14C as radioactive marker, compared to
HGBT, these findings remain controversial and the sensi-
tivity and specificity of the method have been reported at
60–70% and 40%, respectively [1,5,15]. Because it is sim-
pler to administer, more cost-effective and does not
expose the patient to radiation, the HGBT has become the
non-invasive gold standard in the diagnosis of SIBO
[1,3,5].
False positive HGBT findings may occur in the absence of
SIBO in patients with accelerated gastric emptying or with
an accelerated oro-cecal transit time [1,3,4]. False positive
findings may also be returned in patients with prior exten-
sive resection of the small bowel which leads to acceler-
ated intestinal transit as part of a short-bowel syndrome
[10]. A false negative HGBT may occur in patients receiv-
ing antibiotics or with induced reduction in intestinal bac-
Table 4: Prevalence of SIBO in relation to low, medium and high 
stool frequency
SIBO (n = 38)
n % 95%-CI
< 3 stools/day 7 12.5% 6.2 – 23.6%
3–6 stools/day 20 28.6% 19.3 – 40.0%
> 6 stools/day 11 45.8% 27.9 – 64.9%
Table 5: Occurrence of symptoms and symptoms during the test in patients with and without SIBO (multiple responses possible)
All patients
(n = 150)
SIBO
(n = 38)
No SIBO
(n = 112)
n%n % p
Symptoms during the test 19 50,0 21 18,8 0,0002
n %/95% CI %/95% CI %/95% CI
Bloating 29 19.3%
13.8 – 26.4
17 44.7%
30.2 – 60.3
12 10.7%
6.2 – 17.8
Diarrhea 10 6.7%
3.7 – 11.8
6 15.8%
7.4 – 30.4
4 3.6%
1.4 – 8.8
Abdominal pains 9 6.0%
3.2 – 11.0
25 . 3 %
1.5 – 17.3
7 6.3%
3.1 – 12.3
Nausea 2 1.3%
0.4 – 4.7
00 . 0 0 %
--
2 1.8%
0.5 – 6.3
Other 4 2.6%
1.0 – 6.7
25 . 3 %
1.5 – 17.3
2 1.8%
0.5 – 6.3BMC Gastroenterology 2009, 9:61 http://www.biomedcentral.com/1471-230X/9/61
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terial load secondary to bowel preparation, e.g. prior to
colonoscopy [3].
A more difficult problem relates to hydrogen non-produc-
ers, which make up about 10% of the population [1,3]. A
non-producer status was determined in three patients
(2%) in our study, which is low compared to the general
population. On the other hand, a hydrogen non-producer
status was not excluded in all cases by means of the HLBT
but only in those patients reporting typical symptoms
who did not exhibit a significant H2 increase in exhaled
air.
The symptoms of SIBO include weight loss, diarrhea,
meteorism, flatulence and abdominal pain. Correspond-
ingly, patients in the present study with documented
SIBO not only experienced significantly more frequent
symptoms during the HGBT, but also reported a signifi-
cantly higher stool frequency prior to HGBT. In addition,
Crohn's patients who tested positive for SIBO also
showed a significantly lower absolute body weight than
did patients without SIBO.
CDAI served as the parameter expressing disease activity at
the time of test administration. Patients with bacterial
overgrowth exhibited on average only a trend to elevated
levels (166.7 vs. 138.9; p = 0.098). A comparison of the
prevalence of bacterial overgrowth in subgroups of
patients with low (CDAI <150), moderate (CDAI = 150–
300) and high (CDAI >300) disease activity showed no
significant differences. This confirms data reported by
Mishkin et al., who found no statistically significant cor-
relation between CDAI and HGBT results in patients with
CD [10].
Because stool frequency is an important factor in calculat-
ing CDAI, interpreting CDAI values in patients with SIBO
is not always easy. The number of daily bowel movements
was significantly higher in patients with SIBO than in
those without bacterial overgrowth (5.9 vs. 3.7 bowel
movements per day; p = 0.003). Since increased stool fre-
quency is a symptom frequently reported in patients with
SIBO, an increase in CDAI cannot be ascribed exclusively
to an increase in inflammatory activity. We conclude that
the CDAI in patients with CD complicated with SIBO is
less useful to assess disease activity due to the potentially
significant increase in stool frequencies by reasons other
than CD activity.
Reported risk factors for the development of bacterial
overgrowth in patients with CD include surgical proce-
dures involving the gastrointestinal tract, especially ile-
ocecal resection, as well as strictures or fistulae [3,8,10].
Surgery affecting the integrity of the ileocecal valve may be
followed by changes in the bacterial colonization of the
proximal ileum characterized especially by an increase in
the proportion of Gram-negative species [2,7]. The
removal of the physiological barrier represented by the
ileocecal valve allows for a backwash of bacteria-laden
intestinal contents from the colon into the small bowel
[4,7].
Castiglione et al. have shown that the prevalence of SIBO
is higher in patients with prior ileocecal resection than in
those who have not undergone prior surgery (30% vs.
18%; [8]). None of the 61 patients in the study by Rut-
geerts et al. had undergone prior surgery [9]. In the present
study, prior ileocecal resection had been performed in 23
of 38 patients (60.5%) with documented SIBO. Further-
more, nearly half of all patients who had undergone either
prior partial colectomy or multiple resective procedures
affecting the small bowel showed evidence of SIBO, a rate
that was significantly higher than that reported for the
group of patients who had not undergone prior colectomy
or multiple resective procedures. One reason might be a
change, especially a reduction in motility in the bowel fol-
lowing surgery. This may be reflected in data reported by
Castiglione et al., who found a prolongation of oro-cecal
transit time in patients with CD compared to healthy con-
trols [8]. This prolongation of oro-cecal transit time was
especially pronounced in patients with prior ileocecal
resection compared with Crohn's patients who had not
Table 6: Pattern of inflammation and prior surgical procedures in patients with and without SIBO (multiple responses possible)
Pattern of inflammation SIBO (n = 38) No SIBO (n = 112) P
Ileum 27 (71.1%) 72 (64.3%) 0.447
Colon 24 (63.2%) 53 (47.3%) 0.091
Stomach or jejunum 0 (0.0%) 2 (1.8%) 0.407
Colon and small bowel 14 (36.8%) 23 (20.5%) 0.044
Surgical procedure
Bowel resection (all) 23 (60.5%) 56 (50.0%) 0.261
Ileocoecal resection 23 (60.5%) 48 (42.9%) 0.059
Partial colectomy 10 (26.3%) 13 (11.6%) 0.030
Multiple procedures 13 (34.2%) 16 (14.3%) 0.007BMC Gastroenterology 2009, 9:61 http://www.biomedcentral.com/1471-230X/9/61
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undergone prior surgery. It is possible that narrowing of
the intestinal lumen at anastomotic sites or subsequent
recurrence of stenoses may contribute to stasis and pro-
longed transit of intestinal contents.
Fifteen patients in our study who had tested positive for
SIBO had no history of prior surgical procedures. Castigli-
one et al. implicate entero-enteric fistulae and strictures as
possible etiological factors in the development of SIBO in
patients who have not undergone prior surgery [8].
Mishkin et al. describe bacterial overgrowth as an indica-
tor for strictures in patients with CD [10]. In their study,
24 of 25 patients (96%) with radiologically confirmed
strictures exhibited SIBO. Only nine of these patients had
a prior history of ileocecal resection. Stasis of the intesti-
nal contents secondary to strictures has been discussed as
a cause of bacterial overgrowth. In the Rutgeerts trial, of
14 patients with evidence of SIBO, six suffered from radi-
ologically confirmed strictures or fistulae [9]. In the
remaining patients, bacterial overgrowth was believed sec-
ondary to the altered motility of the gastrointestinal tract
occurring in patients with CD.
Strictures and fistulae in patients with chronic inflamma-
tory bowel diseases are often asymptomatic [10]; hence, it
is difficult to make statements on the presence of strictures
or fistulae without radiological or endoscopic findings.
Because no radiological data to exclude fistulae were doc-
umented at the outset of our study, no statement can be
made regarding the presence of entero-enteric fistulae in
our patient collective. However, dysfunction of Bauhin's
valve secondary to chronic inflammation in the terminal
ileum could also be considered a potential promoting fac-
tor for SIBO [9]. Thus, patients with involvement of the
neo- or terminal ileum might be considered at higher risk
for bacterial overgrowth. Although the findings of the
present study showed a strong trend in this direction, data
did not reach the level of statistical significance.
The treatment of bacterial overgrowth includes both sur-
gical procedures aimed at relieving stasis by means of
stricturoplasty or resection of a stenotic bowel segment
and antibiotic therapy [6]. For example, antibiotic therapy
with norfloxacin or amoxicillin/clavulanate was shown to
be significantly more effective than placebo in the treat-
ment of SIBO in patients without inflammatory bowel
disease [10]. Castiglione et al. reported therapeutic success
using metronidazole or ciprofloxacin in patients with CD
[13]. But in many cases, antibiotic treatment may not
show a long-lasting effect because predisposing factors
allowing recurrence remain present and repeated or peri-
odic courses of antibiotics or a combination of antibiotics
are necessary. Therapy of SIBO with probiotics is being
investigated in running studies.
Conclusion
In conclusion, bacterial overgrowth represents a compli-
cation of CD that is often overlooked but may have signif-
icant clinical relevance for patients mimicking acute flare.
It may lead to malnutrition or produce a complex of clin-
ical symptoms that may be impossible to distinguish from
patients' underlying disease. Typically, patients' clinical
symptoms are ascribed to inflammatory activity in the
bowel and treated with anti-inflammatory regimens such
as topical or systemic steroids. Because patients with
chronic inflammatory bowel diseases often experience
malabsorption and gastrointestinal complaints, recogni-
tion and specific therapy of SIBO can be of decisive
importance and must always be considered in the man-
agement of these patients.
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